In the United States, an increasing number of biotech, genomics, and medtech companies with ties to the Chinese Communist Party (CCP) are raising worries about the security of medical and genetic data. China’s sovereign wealth fund has more than $1 trillion in assets, accounting for more than 33% of global sovereign wealth fund holdings. As part of the CCP’s Made in China 2025 initiative, most of this money has been pouring into U.S. biotech companies since 2017. Biotech is particularly identified in the industrial policy as a strategic industry that is eligible for government funding. As a result, Beijing has set aside $100 billion for investment in the industry. China spent $5.1 billion in biotech companies in the United States in 2018, up 25% from the previous year. The People’s Liberation Army (PLA) is participating in biotech research to produce bioweapons … Continue reading The CCP’S Ties to U.S Biotech Companies Are Worth Noticing. MSM Says Otherwise.